D P Ryan

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies
    D P Ryan
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Cancer Res 7:231-42. 2001
  2. ncbi request reprint Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily
    Joseph P Eder
    Division of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 20:3772-84. 2002
  3. ncbi request reprint Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors
    David P Ryan
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Cancer Res 10:2222-30. 2004
  4. ncbi request reprint A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Institute, Boston, Massachusetts, USA
    Dig Dis Sci 51:1033-8. 2006
  5. ncbi request reprint Nonsurgical approaches to colorectal cancer
    David P Ryan
    Tucker Gosnell Gastrointestinal Cancer Center, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Oncologist 11:999-1002. 2006
  6. doi request reprint Mitomycin in anal cancer: still the standard of care
    Joanna Y Chin
    Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 30:4297-301. 2012
  7. pmc Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis
    Bernardo H L Goulart
    Division of Hematology Oncology, Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    J Hematol Oncol 2:13. 2009
  8. ncbi request reprint Anal carcinoma: histology, staging, epidemiology, treatment
    D P Ryan
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Curr Opin Oncol 12:345-52. 2000
  9. ncbi request reprint A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer
    David P Ryan
    Dana Farber Partners Cancer Care Gastrointestinal Cancer Center, Brigham and Women s Hospital, Dana Farber Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, USA
    Cancer Invest 21:505-11. 2003
  10. ncbi request reprint A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors
    David P Ryan
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Cancer 107:2688-97. 2006

Detail Information

Publications89

  1. ncbi request reprint Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies
    D P Ryan
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Cancer Res 7:231-42. 2001
    ..Characterizing the pharmacokinetics of ET-743 during the course of Phase II trials and Phase I combination studies is recommended to assure that this promising new anticancer drug can be used with an acceptable margin of safety...
  2. ncbi request reprint Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily
    Joseph P Eder
    Division of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 20:3772-84. 2002
    ..To perform a phase I trial of recombinant human endostatin (rhEndostatin; EntreMed, Rockville, MD) given as a daily 20-minute intravenous (IV) injection in adult patients with refractory solid tumors...
  3. ncbi request reprint Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors
    David P Ryan
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Cancer Res 10:2222-30. 2004
    ..The main objective of the study was to determine the dose-limiting toxicities and the maximum tolerated dose of BMS-214662 when administered as a single dose i.v. over 1 h every 21 days to patients with advanced solid tumors...
  4. ncbi request reprint A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Institute, Boston, Massachusetts, USA
    Dig Dis Sci 51:1033-8. 2006
    ..4 months. We conclude that while the combination of irinotecan and cisplatin may have activity in aggressive neuroendocrine tumor subtypes, this combination is inactive in patients with well-differentiated neuroendocrine tumors...
  5. ncbi request reprint Nonsurgical approaches to colorectal cancer
    David P Ryan
    Tucker Gosnell Gastrointestinal Cancer Center, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Oncologist 11:999-1002. 2006
    ..At the very least, it is clear that locoregional approaches to debulking tumors are feasible and that their combination with systemic chemotherapy should be investigated...
  6. doi request reprint Mitomycin in anal cancer: still the standard of care
    Joanna Y Chin
    Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 30:4297-301. 2012
    ..Her medical history is otherwise unremarkable, including for HIV, prior abnormal Papanicolaou smears, and other risk factors for human papillomavirus (HPV) exposure...
  7. pmc Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis
    Bernardo H L Goulart
    Division of Hematology Oncology, Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    J Hematol Oncol 2:13. 2009
    ..However, a subgroup of patients survives more than 1 year. We analyzed the survival outcomes of this subgroup and evaluated clinical and pathological factors that might affect survival durations...
  8. ncbi request reprint Anal carcinoma: histology, staging, epidemiology, treatment
    D P Ryan
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Curr Opin Oncol 12:345-52. 2000
    ..The incorporation of cisplatin into the primary chemoradiation treatment of patients with carcinoma of the anal canal is the focus of current studies...
  9. ncbi request reprint A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer
    David P Ryan
    Dana Farber Partners Cancer Care Gastrointestinal Cancer Center, Brigham and Women s Hospital, Dana Farber Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, USA
    Cancer Invest 21:505-11. 2003
    ....
  10. ncbi request reprint A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors
    David P Ryan
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Cancer 107:2688-97. 2006
    ..The authors conducted a Phase I dose-finding trial to study the use of combined bortezomib plus irinotecan in patients with advanced solid tumors...
  11. ncbi request reprint Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901
    David P Ryan
    Massachusetts General Hospital Cancer Center, Boston MA 02114, USA
    J Clin Oncol 24:2557-62. 2006
    ..This phase I/II study evaluated the addition of weekly oxaliplatin to preoperative continuous infusion fluorouracil (FU) and external-beam radiation therapy (RT) in patients with locally advanced rectal adenocarcinoma...
  12. ncbi request reprint A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors
    David P Ryan
    Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Oncologist 7:531-8. 2002
    ..To assess the efficacy, tolerability, and pharmacokinetics of ecteinascidin 743 (ET-743) in patients with advanced gastrointestinal stromal tumors (GISTs)...
  13. ncbi request reprint Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
    David P Ryan
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer 107:2482-9. 2006
    ..The effect of gemcitabine on proteasome inhibition by bortezomib in whole blood was also investigated...
  14. pmc Short-course versus standard chemoradiation in t3 rectal cancer
    Theodore S Hong
    MGH Cancer Center, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts 02114, USA
    Oncologist 16:717-21. 2011
    ..The arrow shows the penetration of the tumor through the thick black line of the muscularis propria...
  15. pmc All nodes lead to chemo
    Lidia Schapira
    Massachusetts General Hospital, Boston 02114, USA
    Oncologist 16:722-5. 2011
  16. ncbi request reprint Management of locally advanced adenocarcinoma of the pancreas
    David P Ryan
    Gastrointestinal Cancer Center, Massachusetts General Hospital, Harvard Medical School, Cox 640, 100 Blossom Street, Boston, MA 02114, USA
    Hematol Oncol Clin North Am 16:95-103. 2002
    ..The introduction of gemcitabine into chemoradiotherapy regimens may provide additional improvements in the management of patients. Preoperative therapy has proved feasible but has not shown improvement in overall survival...
  17. ncbi request reprint A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma
    David P Ryan
    Gastrointestinal Cancer Center, Dana Farber Partners Cancer Care, Boston, Massachusetts, USA
    Cancer 94:97-103. 2002
    ..Chemotherapy with gemcitabine is the standard first-line treatment. In a Phase II trial at one academic cancer center, the clinical safety and activity of combining gemcitabine and docetaxel were assessed...
  18. ncbi request reprint Rectal cancer: integrating oxaliplatin into chemoradiation studies
    D P Ryan
    Gastrointestinal Cancer Center, Massachusetts General Hospital Cancer Center, Dana Farber Partners Cancer Care, Boston, Massachusetts, USA
    Oncology (Williston Park) 14:38-41. 2000
    ....
  19. ncbi request reprint Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study
    R Garcia-Carbonero
    Dana Farber Cancer Institute, Harvard Medical School, 44 Binney St, Boston, Massachusetts 02115, USA
    J Clin Oncol 23:5484-92. 2005
    ..To evaluate the response rate, toxicity profile, and pharmacokinetics of ecteinascidin-743 (ET-743) as first-line therapy in patients with unresectable advanced soft tissue sarcoma (STS)...
  20. ncbi request reprint Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 25:4787-92. 2007
    ..We evaluated an oral regimen of capecitabine and erlotinib in patients with advanced pancreatic cancer who had experienced treatment failure with standard first-line therapy with gemcitabine...
  21. ncbi request reprint Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Colorectal Cancer 6:208-13. 2006
    ....
  22. pmc A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
    J A Chan
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 22:1367-73. 2011
    ..We carried out a multi-institutional phase II study of cetuximab, a monoclonal antibody against EGFR, in patients with unresectable or metastatic esophageal or gastric adenocarcinoma...
  23. doi request reprint Activity of sunitinib in patients with advanced neuroendocrine tumors
    Matthew H Kulke
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:3403-10. 2008
    ..We evaluated the efficacy of sunitinib in a two-cohort, phase II study of advanced carcinoid and pancreatic neuroendocrine tumor patients...
  24. ncbi request reprint Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy
    R Garcia-Carbonero
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Harvard Medical School, Shields Warren Bldg, Room G530, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 22:1480-90. 2004
    ....
  25. pmc Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer
    P C Enzinger
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 20:475-80. 2009
    ..Recent studies have examined the addition of docetaxel to fluorouracil and cisplatin in advanced esophagogastric cancer...
  26. ncbi request reprint Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 11:6650-6. 2005
    ..Abnormalities of EGFR and related pathways may have an effect on responsiveness of advanced colorectal cancer to combination chemotherapy with gefitinib...
  27. ncbi request reprint Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas
    John V Heymach
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Clin Cancer Res 10:5732-40. 2004
    ..This Phase II study was conducted to investigate the safety and efficacy of SU5416 for patients with soft tissue sarcomas...
  28. ncbi request reprint CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Virchows Arch 450:529-37. 2007
    ..Additional studies are necessary to examine the role of DNA methylation in treatment efficacy...
  29. ncbi request reprint Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:401-6. 2006
    ..We evaluated the efficacy of an oral regimen of temozolomide and thalidomide in patients with metastatic carcinoid, pheochromocytoma, or pancreatic neuroendocrine tumors...
  30. ncbi request reprint Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer
    J A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 18:1185-9. 2007
    ..Targeting the epidermal growth factor receptor and angiogenesis have proven useful strategies against metastatic colorectal cancer. The benefit of combining inhibitors of both pathways is unknown...
  31. ncbi request reprint A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma
    Peter C Enzinger
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Dig Dis Sci 50:2218-23. 2005
    ..When used as a single-agent, a tri-weekly schedule may be preferable for this patient population...
  32. doi request reprint Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or older
    David T Miyamoto
    Harvard Radiation Oncology Program, Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 77:1171-7. 2010
    ..To review the outcomes and tolerability of full-dose chemoradiation in elderly patients aged 75 years or older with localized pancreatic cancer...
  33. ncbi request reprint Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours
    Suzanne George
    Dana Farber Cancer Institute, Massachusetts General Hospital, Ludwig Center for Cancer Research at Dana Farber Harvard, Harvard Medical School, Boston, MA, USA
    Eur J Cancer 42:864-70. 2006
    ..It remains unclear whether addition of growth factors might improve tolerability for imatininb in combination with cytotoxic chemotherapy...
  34. ncbi request reprint A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer
    Matthew H Kulke
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer J 8:395-9. 2002
    ..We therefore assessed the efficacy of troglitazone in the treatment of metastatic colon cancer in humans...
  35. ncbi request reprint A phase II study of docetaxel in patients with metastatic carcinoid tumors
    Matthew H Kulke
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Invest 22:353-9. 2004
    ..Twenty-one patients with metastatic carcinoid tumors were treated with docetaxel. Although the treatment was well tolerated, no objective radiologic responses were observed. Novel, more effective agents are needed for this disease...
  36. ncbi request reprint Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity
    Thomas A Puchalski
    Dana Farber Partners Cancer Care, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Chemother Pharmacol 50:309-19. 2002
    ....
  37. ncbi request reprint Case records of the Massachusetts General Hospital. Case 20-2005. A 58-year-old man with locally advanced pancreatic cancer
    David P Ryan
    Department of Hematology and Oncology, Massachusetts General Hospital, Boston, USA
    N Engl J Med 352:2734-41. 2005
  38. ncbi request reprint Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:3555-61. 2006
    ..We therefore performed a multicenter phase II study of rhEndostatin in patients with carcinoid or pancreatic neuroendocrine tumors...
  39. ncbi request reprint Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Chemother Pharmacol 60:661-70. 2007
    ....
  40. doi request reprint The role of targeted agents in preoperative chemoradiation for rectal cancer
    Raymond C Wadlow
    Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer 116:3537-48. 2010
    ....
  41. doi request reprint Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy
    Walter J Zawacki
    Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Vasc Interv Radiol 20:624-7; quiz 571. 2009
    ..A hypothesis was tested that the mean interval between bevacizumab administration and port placement was shorter in patients who had dehiscence than in those who did not...
  42. doi request reprint Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Lancet Oncol 11:48-54. 2010
    ....
  43. doi request reprint Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head
    Theodore S Hong
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 79:151-7. 2011
    ..To evaluate the safety of 1 week of chemoradiation with proton beam therapy and capecitabine followed by early surgery...
  44. doi request reprint Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors
    Andrew X Zhu
    Massachusetts General Hospital, Dana Farber Harvard Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Cancer Res 15:374-81. 2009
    ..A phase I study was conducted to determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of gimatecan, a lipophilic camptothecin analogue, administered orally once a week for 3 weeks...
  45. pmc Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 27:193-8. 2009
    ..We performed a multi-institutional, single-arm, phase II study of RAD001(everolimus), an oral inhibitor of mTOR, in patients who experienced treatment failure on first-line therapy with gemcitabine...
  46. ncbi request reprint Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Dig Dis Sci 53:564-70. 2008
    ....
  47. ncbi request reprint Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Cancer 110:581-9. 2007
    ..A phase 2 study was performed with cetuximab, a chimeric monoclonal antibody that binds specifically to EGFR, in patients with advanced HCC...
  48. ncbi request reprint Emerging therapies for colorectal cancer
    Aram F Hezel
    Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    Expert Opin Investig Drugs 16:867-76. 2007
    ..In this review, the authors summarize agents in development, modulating several of the most promising molecules and pathways that are thought to be relevant to colorectal cancer...
  49. pmc Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study
    Andrew X Zhu
    Division of Hematology Oncology, Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 27:3027-35. 2009
    ..To assess the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) and explore biomarkers for sunitinib response...
  50. ncbi request reprint Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors
    Joseph P Eder
    Dana Farber Cancer Institute, Department of Medical Oncology and Brigham and Women s Hospital, Dana Farber Harvard Cancer Center, Harvard Medical School, Shields Warren Building 460, 44 Binney Street, Boston, MA 02115, USA
    Cancer Chemother Pharmacol 58:107-16. 2006
    ..v. infusion was initiated to determine if the duration of maximum FT inhibition could be significantly extended by prolonging the infusion time and increasing the frequency of administration...
  51. ncbi request reprint Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer
    Andrew X Zhu
    Massachusetts General Hospital, Division of Hematology Oncology, Harvard Medical School, Boston, MA, USA
    Clin Colorectal Cancer 3:225-34. 2004
    ..V. bolus 5-FU. The present study offers useful themes for undertaking larger prospective pharmacogenetic studies in the future...
  52. ncbi request reprint Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors
    Johanna C Bendell
    Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 103:1925-31. 2005
    ..The purpose of the current open-label, Phase I dose-escalation trial was to evaluate the combination of tezacitabine and 5-fluorouracil (5-FU) in the treatment of patients with advanced solid tumors...
  53. pmc Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
    Christopher G Willett
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Nat Med 10:145-7. 2004
    ..These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors...
  54. ncbi request reprint Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors
    Anna Berkenblit
    Beth Israel Deaconess Medical Center, and Harvard Cancer Center, Boston, MA, USA
    Clin Cancer Res 13:584-90. 2007
    ..A phase I clinical trial was undertaken to determine the maximum tolerated dose, toxicity profile, and pharmacokinetics of STA-4783 in combination with paclitaxel...
  55. ncbi request reprint A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies
    Joseph P Eder
    Dana Farber Harvard Cancer Care, Harvard Medical School, Boston, MA 02115, USA
    Invest New Drugs 22:139-50. 2004
    ..The objectives of this phase I trial were to determine the maximum tolerated dose (MTD), the dose limiting toxicities (DLTs), and the pharmacokinetics of PKC412 when co-administered with 5-Fluorouracil (5-FU)...
  56. ncbi request reprint Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors
    Jeffrey G Supko
    Massachusetts General Hospital, Dana Farber Harvard Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Cancer Res 9:5178-86. 2003
    ..A Phase I trial was undertaken to determine the maximum tolerated dose (MTD), dose-limiting toxicities, and pharmacokinetic behavior of KRN5500 given as a 1-h i.v. infusion for 5 consecutive days every 3 weeks...
  57. ncbi request reprint A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors
    M Dror Michaelson
    Department of Hematology Oncology, Massachusetts General Hospital, Cox Building Room 640, 100 Blossom Street, Boston, MA 02114, USA
    Cancer 97:148-54. 2003
    ..This trial examined the combination of these two oral agents in patients with metastatic solid tumors...
  58. ncbi request reprint A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center and Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Oncologist 10:392-8. 2005
    ..Therefore, we performed a phase II study using the combination of epirubicin and thalidomide in patients with unresectable and metastatic HCC...
  59. ncbi request reprint Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:1892-7. 2006
    ..To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer...
  60. ncbi request reprint Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 24:1898-903. 2006
    ....
  61. ncbi request reprint A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma
    Charles S Fuchs
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 94:3186-91. 2002
    ..A recent trial reported a moderate antitumor activity for gemcitabine among Asian patients with advanced hepatocellular carcinoma. This led to our examination of the efficacy and tolerability of the drug in a population of U.S. patients...
  62. ncbi request reprint Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer
    Andrew X Zhu
    Massachusetts General Hospital, 100 Blossom Street, Cox 640, Boston, MA 02114, USA
    Cancer Chemother Pharmacol 59:285-93. 2007
    ....
  63. ncbi request reprint Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Brigham Women s Hospital, Boston, MA 02115, USA
    Clin Colorectal Cancer 6:59-65. 2006
    ..Whether these results apply to other cancer types is unknown but worthy of further study...
  64. ncbi request reprint A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors
    Michael V Seiden
    Department of Medicine, Massachusetts General Hospital, Boston 02114, USA
    Clin Cancer Res 8:691-7. 2002
    ..To determine whether agents that target topoisomerase I and II could be administered sequentially...
  65. doi request reprint A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors
    J R Strosberg
    Department of GI Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, Florida 33612, USA
    Endocr Relat Cancer 20:383-90. 2013
    ..Although well tolerated, treatment with single-agent ganitumab failed to result in significant tumor responses among patients with metastatic well-differentiated carcinoid or pNET...
  66. doi request reprint Toxicity and outcomes after chemoradiation for esophageal cancer in patients age 75 or older
    R H Mak
    Harvard Radiation Oncology Program, Massachusetts General Hospital, Boston, Massachusetts, USA
    Dis Esophagus 23:316-23. 2010
    ..In conclusion, elderly patients experienced substantial morbidity from chemoradiation, and long-term survival was low. Future efforts to improve treatment tolerability in the elderly are needed...
  67. ncbi request reprint Adjuvant therapy for pancreatic cancer: a review
    Dan S Zuckerman
    Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer 112:243-9. 2008
    ..They also reviewed preliminary data from more recent adjuvant trials and explored the possible benefits of a neoadjuvant approach...
  68. pmc Quality of life in pancreatic cancer: analysis by stage and treatment
    Stefano Crippa
    Wang Ambulatory Care Center 460, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, Boston, MA 02114, USA
    J Gastrointest Surg 12:783-93; discussion 793-4. 2008
    ..One-year survival was 74%, 30%, and 16% for groups 1, 2, and 3 respectively (p=0.001). Pancreatic cancer prognosis is still dismal. In addition to long-term survival benefits, surgery impacts favorably quality of life...
  69. doi request reprint MDM2 promoter polymorphism and pancreatic cancer risk and prognosis
    Kofi Asomaning
    Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA
    Clin Cancer Res 14:4010-5. 2008
    ..We hypothesized that the G allele is also associated with increased risk and worse outcome in pancreatic cancer...
  70. ncbi request reprint Dosimetric feasibility of hypofractionated proton radiotherapy for neoadjuvant pancreatic cancer treatment
    Kevin R Kozak
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 68:1557-66. 2007
    ..To evaluate tumor and normal tissue dosimetry of a 5 cobalt gray equivalent (CGE) x 5 fraction proton radiotherapy schedule, before initiating a clinical trial of neoadjuvant, short-course proton radiotherapy for pancreatic adenocarcinoma...
  71. pmc O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 15:338-45. 2009
    ..We evaluated the prevalence of MGMT deficiency in neuroendocrine tumors and correlated MGMT deficiency with treatment response to temozolomide-based regimens...
  72. ncbi request reprint Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations
    Jennifer F Tseng
    Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Pancreatology 5:67-74. 2005
    ..We sought to determine whether patients undergoing postresection or primary medical treatment for pancreatic adenocarcinoma were immunocompetent...
  73. ncbi request reprint Current perspectives on anal cancer
    Johanna C Bendell
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Oncology (Williston Park) 17:492-7, 502-3; discussion 503, 507-9. 2003
    ..Current areas under investigation include the incorporation of platinum agents into the chemotherapy regimen and the use of cytologic screening studies for high-risk populations...
  74. pmc Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study
    M D Michaelson
    Massachusetts General Hospital Cancer Center, 55 Fruit Street, Yawkey 7, Boston, MA 02114, USA
    Br J Cancer 108:1393-401. 2013
    ..This phase I, dose-finding study determined the maximum tolerated dose (MTD), safety, and pharmacokinetics of sunitinib plus gemcitabine in patients with advanced solid tumours...
  75. ncbi request reprint Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy
    John G Gribben
    Department of Medical Oncology, Dana Farber Cancer Institute and Division of Medical Oncology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Cancer Res 11:4430-6. 2005
    ..Anti-CYP1B1-specific T cells kill CYP1B1-expressing tumors, providing the rationale to examine CYP1B1 as a target for immunotherapy...
  76. pmc Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer
    Christopher G Willett
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Ann Surg 241:295-9. 2005
    ..To analyze the effects of a treatment program of intraoperative electron beam radiation therapy (IOERT) and external beam radiation therapy and chemotherapy on the outcome of patients with unresectable or locally advanced pancreatic cancer...
  77. pmc Scan? Cure? Sure!
    Richard M Goldberg
    University of North CarolinaChapel Hill, USA
    Oncologist 16:254-6. 2011
    ..Is CT scanning appropriate in the follow-up of colon cancer patients? (This case was presented at Massachusetts General Hospital Cancer Center.)...
  78. ncbi request reprint Locally advanced pancreatic cancer
    Christopher G Willett
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 23:4538-44. 2005
    ..These treatments include external-beam irradiation with and without fluorouracil-based chemotherapy, intraoperative irradiation, and, more recently, external-beam irradiation with new systemic targeted agents...
  79. doi request reprint Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinoma
    Paul Wheatley-Price
    Department of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Hospital, Toronto, Ontario, Canada
    Cancer 112:1037-42. 2008
    ..Myeloperoxidase (MPO) and superoxide dismutase (SOD2) are enzymes that regulate reactive oxygen species and contain recognized single nucleotide polymorphisms (SNPs) that confer altered enzyme activity...
  80. ncbi request reprint A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors
    Linda L Garland
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
    Clin Cancer Res 12:4274-82. 2006
    ..We conducted a dose escalation study of CI-1033 with docetaxel to assess the safety profile and pharmacokinetics of the combination and to establish the maximum tolerated dose...
  81. ncbi request reprint Pancreatoblastoma in a teenage patient
    Johanna C Bendell
    Division of Oncology and Transplantation, Room 3806 Red Zone, Duke South Clinics, Duke University Medical Center, DUMC 3505, Durham, NC 27710, USA
    Clin Adv Hematol Oncol 4:150-3; discussion 154. 2006
  82. ncbi request reprint Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors
    Casey Cunningham
    Tyler Cancer Center, Texas, USA
    Clin Cancer Res 11:7825-33. 2005
    ..To determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics of tasidotin (ILX651), a dolastatin-15 analogue, when administered on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors...
  83. ncbi request reprint The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer
    A David McCollum
    Texas Oncology, PA, and Baylor Sammons Cancer Center, Dallas, TX 75246, USA
    Am J Clin Oncol 29:40-4. 2006
    ..We conducted a multicenter, phase II study to examine the combination of capecitabine and thalidomide (Cape/Thal) in patients with refractory metastatic CRC...
  84. ncbi request reprint Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors
    A David McCollum
    Baylor University Medical Center Charles A Sammons Cancer Center, Dallas, Texas 75246, USA
    Am J Clin Oncol 27:485-8. 2004
    ..However, a recent review failed to confirm high antitumor activity in patients with advanced PETs...
  85. ncbi request reprint Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Clin Cancer Res 12:4283-7. 2006
    ..Given recent reports of TKI-responsive cases of esophageal and pancreatic cancer, this study was designed to determine the prevalence of EGFR mutations in these gastrointestinal cancers...
  86. doi request reprint Rectal cancer at the crossroads: the dilemma of clinically staged T3, N0, M0 disease
    Lisa A Kachnic
    J Clin Oncol 26:350-1. 2008
  87. ncbi request reprint Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients
    Christopher G Willett
    J Clin Oncol 23:8136-9. 2005
  88. doi request reprint Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study
    Peter S Kozuch
    Continuum Cancer Centers of New York, St Luke s Roosevelt Hospital, New York, NY, USA
    J Clin Oncol 26:2320-6. 2008
    ..To evaluate the efficacy and toxicity of bortezomib with or without irinotecan, in patients with relapsed or refractory colorectal cancer (CRC)...
  89. pmc A blended knowledge translation initiative to improve colorectal cancer staging [ISRCTN56824239]
    Frances C Wright
    Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada
    BMC Health Serv Res 6:4. 2006
    ....